November 24, 2008 - For breast cancer patients who underwent a mastectomy who undergo radiation therapy after immediate breast reconstruction, autologous tissue reconstruction provides fewer long-term complications and better cosmetic results than tissue expander and implant reconstruction, according to a study in the November issue of the “International Journal of Radiation Oncology*Biology*Physics,” the official journal of the American Society for Therapeutic Radiology and Oncology (ASTRO).

After undergoing a mastectomy (surgical removal of the breast), many women choose to have a breast reconstruction procedure performed immediately to better cope with the psychological and esthetic side effects of the surgery. However, the reconstruction can complicate radiation therapy treatments and sometimes radiation can negatively affect the outcome of reconstruction and increase the risk of long-term complications.

With radiation therapy increasingly becoming the standard of care for high-risk breast cancer patients after mastectomy, this can cause a problem for both patients and their radiation oncologists.

Researchers at the Department of Radiation Oncology at Long Island Radiation Therapy in Garden City, N.Y., the Department of Surgery at Long Island Jewish Hospital in New Hyde Park, N.Y., the Department of Surgery at North Shore University Hospital in Manhasset, N.Y. and the Department of Surgery at Winthrop University Hospital in Mineola, N.Y., sought to determine if the type of reconstruction performed on women who were receiving radiation after a mastectomy had an impact on their long-term outcomes.

Two types of reconstruction are available for patients undergoing mastectomy for breast cancer: ATR (autologous tissue reconstruction), which involves the placement of a tissue flap - most commonly from the transverse rectus abdominus muscle - as a breast mound, and TE/I (tissue expander and implant reconstruction), which involves placing an inflatable tissue expander over the chest wall and exchanging it for a permanent implant at a later date.

This study involved the largest reported series of patients who sequentially underwent mastectomy, immediate reconstruction and postmastectomy radiation therapy. Ninety-two patients were observed for 38 months following their reconstruction and radiation treatments, and researchers found that ATR is better tolerated by breast cancer patients because it is associated with fewer long-term complications and better cosmetic results than TE/I.

None of the 23 ATR patients required surgical intervention, while 33 percent of TE/I patients needed surgery to correct a problem with their reconstruction. Eighty-three percent of ATR patients reported acceptable cosmetic outcome, as opposed to only 54 percent of TE/I patients.

“This study is useful for patients who are candidates for either ATR or TE/I and are making a decision with regards to reconstruction technique,” said Jigna Jhaveri, M.D., lead author of the study and a radiation oncologist at Advanced Radiation Centers of New York in Hauppauge, N.Y. “Our study provides evidence that patients who undergo autologous tissue reconstruction and radiation therapy have fewer long term complications and better cosmetic outcomes than those who undergo tissue expander/ implant reconstruction and radiation therapy.”

For more information: www.astro.org


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now